Healthcare
PharmaRoth Labs, Inc.(ROTH)
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 20, 2025 → Jun 15, 2026
- Market Cap
- —
- Revenue Growth
- -31.1%
- EPS Growth
- +66.7%
- Dividend Yield
- 0.0%
Coverage: 248 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PharmaRoth Labs, Inc. (ROTH) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -31.1%, EPS growth of +66.7%, a dividend yield of 0.0%. What stands out right now is revenue -31.1%, EPS +66.7%, free cash flow 0.0% with operating margin -50.4% and ROIC 29.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ROTH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-31.1% vs +7.6% peer median
Operating Margin
Below sector median
-50.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -31.1% and EPS is at +66.7%, with operating margin around -50.4%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ROTH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ROTH Max Drawdown
-99.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ROTH and SPY.
Company Overview
PharmaRoth Labs, Inc.
Other OTC
PharmaRoth Labs, Inc. operates as a nutraceutical company worldwide. It focuses on producing, marketing, and distributing Sucanon, an herbal-based nutraceutical treatment for type-2 diabetes. The company was formerly known as Fero Industries Inc. and changed its name to PharmaRoth Labs, Inc. in March 2013. PharmaRoth Labs, Inc. was founded in 2000 and is based in Las Vegas, Nevada.
- Leadership
- Luis Manuel Ornelas Lopez
- IPO Date
- Dec 11, 2008
- Employees
- 2
- Street Address
- 8250 West Charleston Boulevard
- Mailing
- Las Vegas, NV
- Region
- Las Vegas, NV, US
- Reporting Currency
- USD
- Investor Line
- 212-541-6222
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 0.2
- Price/Book
- —
Growth
- Revenue
- -31.1%
- EPS
- +66.7%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 40.0%
- Operating Margin
- -50.4%
- Net Margin
- -50.4%
- ROE
- 17.7%
- ROIC
- 29.6%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.35
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.